Oct 06, 2025 • Zacks Commentary
BULLISH
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Oct 03, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
Oct 02, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Sep 30, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
Sep 29, 2025 • Zacks Commentary
BULLISH
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada ( KMDA Quick QuoteKMDA - ) and Illumina ( ILMN Quick QuoteILMN - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer ...
Sep 26, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?